<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02524301</url>
  </required_header>
  <id_info>
    <org_study_id>0908019</org_study_id>
    <nct_id>NCT02524301</nct_id>
  </id_info>
  <brief_title>Evaluation of Brain Opioid Receptor Activity in Anorexia Nervosa : a PET [11C]Diprenorphine Study</brief_title>
  <official_title>Evaluation of Brain Opioid Receptor Activity in Anorexia Nervosa : a PET [11C]Diprenorphine Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The place of opioid system in anorexia nervosa (AN) physiopathology is still unclear.
      Conflicting results were published on cerebral spinal fluid or peripheral levels in anorexia
      nervosa. However, no data have been reported on opioid cerebral activity. Diprenorphine is a
      ligand with non-selective binding to opiate receptors µ, κ and δ capable to assess the
      interaction between endogenous opioids and their receptors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>[11C]diprenorphine binding potential</measure>
    <time_frame>week 2</time_frame>
    <description>Value of [11C]diprenorphine binding potential (BP) in predefined brains regions [11C] diprenorphine BP will be evaluated by brain positron emission tomography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation [11C]diprenorphine binding potential</measure>
    <time_frame>week 2</time_frame>
    <description>Correlation between [11C]diprenorphine binding potential and plasma endogenous opioid levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation [11C]diprenorphine binding potential</measure>
    <time_frame>week 2</time_frame>
    <description>Correlation between [11C]diprenorphine binding potential and psychometric score evaluating addictive behavior, reward and positive reinforcement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation [11C]diprenorphine binding potential</measure>
    <time_frame>week 2</time_frame>
    <description>Correlation between [11C]diprenorphine binding potential and appetite regulating hormones</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation [11C]diprenorphine binding potential</measure>
    <time_frame>week 2</time_frame>
    <description>Correlation between [11C]diprenorphine binding potential and LH response during GnRH test</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Body Dysmorphic Disorders</condition>
  <condition>Anorexia</condition>
  <arm_group>
    <arm_group_label>anorexia nervosa patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cerebral [11C]diprenorphine Binding Potential measured by Positron emission Tomography (PET)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recovered anorexia nervosa patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cerebral [11C]diprenorphine Binding Potential measured by Positron emission Tomography (PET)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volonteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cerebral [11C]diprenorphine Binding Potential measured by Positron emission Tomography (PET)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Positron Emission Tomography using [11C]diprenorphine</intervention_name>
    <description>PET using [11C]diprenorphine</description>
    <arm_group_label>anorexia nervosa patients</arm_group_label>
    <arm_group_label>Recovered anorexia nervosa patients</arm_group_label>
    <arm_group_label>Healthy Volonteers</arm_group_label>
    <other_name>PET</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AN patients DSM IV criteria including amenorrhea BMI &lt; 17.5 kg/m² and abnormal
             nutritional markers Group 1 (N=15) : long period of / recurrent weight loss (&gt; 2 yrs)
             Group 2 (N=15) : recent weight loss (6 to 12 months)

          -  Recovered AN patients History of AN Weight recovery and BMI &gt; 18.5 kg/m², stable for
             at least 12 months Normal nutritional markers Group 1 (N=15) : menses recovery after
             bodyweight stabilization Group 2 (N=15) : long persistence of amenorrhea (&gt; 12 months)
             despite weight recovery

          -  Healthy volunteers (N=15) BMI between 18.5 and 25 kg/m², normal nutritional markers,
             absence of psychiatric or organic pathology

          -  For all subjects Women 18-35 yrs Written and sign consent Affiliation to health
             insurance

        Exclusion Criteria:

          -  History of heart failure

          -  Psychotropic treatment , antiepileptics

          -  Ongoing or suspected pregnancy, positive beta HCG test before brain imaging

          -  Intense physical activity

          -  Constrains for MRI (ferromagnetic implants or claustrophobia)

          -  Refusal to be informed in case of incidentaloma revealed by brain imaging

          -  Refusal for written consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Estour, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Saint-Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruno Estour, PHD</last_name>
    <phone>(0)4 77 12 77 27</phone>
    <phone_ext>+33</phone_ext>
    <email>bruno.estour@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bruno Estour, PhD</last_name>
    <phone>(0)477127727</phone>
    <phone_ext>+33</phone_ext>
    <email>bruno.estour@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Estour, PHD</last_name>
      <email>bruno.estour@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno Estour</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natacha Germain</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bogdan Galusca</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2015</study_first_submitted>
  <study_first_submitted_qc>August 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2015</study_first_posted>
  <last_update_submitted>May 29, 2017</last_update_submitted>
  <last_update_submitted_qc>May 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anorexia nervosa</keyword>
  <keyword>opioid receptors</keyword>
  <keyword>Positron emission tomography (PET)</keyword>
  <keyword>diprenorphine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Anorexia Nervosa</mesh_term>
    <mesh_term>Body Dysmorphic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Diprenorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

